04.14.21 How To Improve FDA Inspection Readiness By Mining Publicly Available Data
YPrime eCOA Platform Isn’t it about time for a globally proven eCOA technology that gives you peace of mind? One that provides a better user experience for patients, sites, and sponsors? YPrime’s eCOA platform delivers even the most complex protocol seamlessly. Developed to integrate intelligently with your other technologies, all modalities are available for site- or home-based trials and paired with secure web backup for guaranteed accuracy and confident, informed decision-making.
It’s Time for the Prime eCOA Solution: It’s Time for YPrime.
Featured Editorial
02.17.21 Why Did Veeva Become A Public Benefit Corporation?
With the spread of SARS-CoV-2 (COVID-19) intensifying, scientists, together with pharmaceutical companies, are reinventing the approach of how to bring life-saving drugs to market. Attend this webinar to learn more about bringing life-saving drugs to market faster without impacting product quality, safety, or efficacy and the impacts and comparisons of classic platforms vs. new-generation platforms. And more!
By Ed Miseta, chief editor, Clinical Leader
On February 1, 2021, Veeva Systems officially became a Public Benefit Corporation (PBC). With this move, it becomes the first technology company supporting life sciences to transition to a PBC and it is also the first publicly traded corporation in any industry to make that move. How will the designation benefit the company?
02.08.21 Janssen s Best Practices For Patient Diversity Success
eCOA/ePRO providers and sponsor/CRO organizations will gain valuable insight using this report. eCOA/ePRO providers: Learn how your company performs against competitors. Discover where performance exceeds expectations so you can differentiate your offerings from competitors. For sponsors/CROs: Compare your company’s outsourcing philosophy to that of the broader industry. Evaluate your provider selection process. Explore new providers and understand how they have performed for industry peers. Free preview.
Featured Editorial
By Ed Miseta, chief editor, Clinical Leader
The public s understanding of clinical research has increased as a result of the pandemic. However, that will not necessarily lead to improved patient recruitment in trials, especially among the much-needed minority populations. Cassandra Smith, director, diversity and inclusion in clinical trials at Janssen